CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) regimens for HIV-infected individuals. Polymorphisms of the CYP2B6 gene influence drug levels in plasma and possibly virological outcomes. The aim of this study was to explore the potential impact of CYP2B6 genotype and haplotype variation on the risk of developing EFV/NVP drug resistance mutations (DRMs) in HIV-1 patients receiving EFV-/NVP-containing regimens in Botswana.

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana / Maseng, Monkgomotsi J; Tawe, Leabaneng; Thami, Prisca K; Seatla, Kaelo K; Moyo, Sikhulile; Martinelli, Axel; Kasvosve, Ishmael; Novitsky, Vladimir; Essex, Max; Russo, Gianluca; Gaseitsiwe, Simani; Paganotti, Giacomo M. - In: PHARMACOGENOMICS AND PERSONALIZED MEDICINE. - ISSN 1178-7066. - 14(2021), pp. 335-347.

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana

Russo, Gianluca
Ultimo
;
Paganotti, Giacomo M
2021

Abstract

CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) regimens for HIV-infected individuals. Polymorphisms of the CYP2B6 gene influence drug levels in plasma and possibly virological outcomes. The aim of this study was to explore the potential impact of CYP2B6 genotype and haplotype variation on the risk of developing EFV/NVP drug resistance mutations (DRMs) in HIV-1 patients receiving EFV-/NVP-containing regimens in Botswana.
File allegati a questo prodotto
File Dimensione Formato  
Maseng_Association_2021.pdf

accesso aperto

Note: Senior co-authorship (see acknowledgment section of the paper)
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 665.09 kB
Formato Adobe PDF
665.09 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1524841
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
social impact